OMERACT 巨细胞动脉炎超声评分:评估随访期间复发风险的潜在预测结局
这项多中心回顾性研究纳入76例巨细胞动脉炎患者,在基线、3个月和6个月进行超声评估并计算OMERACT巨细胞动脉炎超声评分(OGUS)。结果显示,6个月未复发患者OGUS显著改善,而复发患者无显著变化;0-6个月OGUS改善幅度在复发患者中更低,在达到缓解的患者中更大。作者认为,随访期间OGUS无改善可用于评估6个月复发概率及未缓解状态。
要点
- 6个月未复发患者OGUS从基线至6个月显著改善(1.18降至0.99,P=0.004)。
- 6个月复发患者OGUS在3个月和6个月均无显著变化。
- 0-6个月OGUS改善幅度在复发患者中更低(P=0.037),在缓解患者中更大(P=0.001)。
核心结论
- 作者认为,巨细胞动脉炎随访期间OGUS无改善可用于评估6个月复发概率及未缓解状态。
研究设计与样本
- 本研究为多中心回顾性研究,纳入转诊至两家美国巨细胞动脉炎快速通道诊所的76例巨细胞动脉炎患者,随访2年。
- 患者在基线、3个月和6个月接受超声评估,并在3个月和6个月核查EULAR缓解与复发标准。
主要发现
- 共纳入76例患者(平均年龄77.2岁,女性55.3%),6个月时19例(26%)复发,其中14例(19.1%)为轻微复发、5例(6.8%)为主要复发。
- 6个月时达到EULAR缓解者32例(43.8%)。
- 未复发患者OGUS从基线至6个月显著改善(1.18降至0.99,P=0.004),从3个月至6个月亦显著改善(1.08降至0.99,P=0.04)。
- 复发患者OGUS在3个月(1.17至1.17,P=0.736)和6个月(1.17至1.21,P=0.343)均无显著变化。
- 0-6个月OGUS平均改善幅度在复发患者中更低(-0.1至0.16,P=0.037),在6个月达到缓解的患者中更大(0.28至-0.07,P=0.001)。
关键数值与推荐
- OGUS基线至3个月和3个月至6个月的标准化均数差分别为-0.25和-0.38。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to determine whether the OMERACT GCA US Score (OGUS) change after treatment can be used for assessing the probability of relapse. METHODS: This study was a multicentre retrospective study of GCA patients referred to two US GCA fast-track clinics over 2 years. The patients underwent US evaluation at baseline, and at 3 and 6 months. EULAR criteria for remission and relapse were checked at 3 and 6 months. OGUS changes at 0-3 months and 0-6 months were compared between patients with and without relapse at 6 months, as well as between those with and without remission at 6 months. RESULTS: A total of 76 patients were included (mean age 77.2 years, 55.3% females). Nineteen (26%) patients relapsed at 6 months, of whom 14 (19.1%) showed a minor relapse and 5 (6.8%) a major relapse. EULAR remission at 6 months was achieved in 32 (43.8%) patients. The standardized mean difference in OGUS between baseline and 3 months and between 3 months and 6 months was -0.25 and -0.38, respectively. OGUS significantly improved between baseline and 6 months (1.18 to 0.99, P = 0.004) and from 3-6 months (1.08 to 0.99, P = 0.04) in non-relapsing patients, whereas no significant changes at 3 (1.17 to 1.17; P = 0.736) and 6 months (1.17 to 1.21; P = 0.343) months were observed in those who experienced relapse. The mean 0-6-month OGUS improvement was lower in patients who relapsed (-0.1 to 0.16, P = 0.037). The mean 0-6-months OGUS improvement (decrease) was greater in patients who achieved remission at 6 months (0.28 to -0.07, P = 0.001). CONCLUSION: The absence of OGUS improvement during follow-up in GCA may be used to assess the probability of relapse and the absence of remission at 6 months.
引用
- Molina-Collada J, Monjo-Henry I, Fernández-Fernández E, et al. The OMERACT giant cell arteritis ultrasonography score: a potential predictive outcome for assessing the risk of relapse during follow-up. Rheumatology (Oxford). 2025. PMID: 38718182. doi:10.1093/rheumatology/keae260
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。